Drugs for Weight Management — Coverage Criteria and Authorization
Criteria for medical necessity, authorization lengths, and reauthorization requirements for prescription drugs used for chronic weight management and related indications; intended for providers and pharmacy reviewers.
Updated Wegovy (semaglutide) coverage criteria to include use in certain individuals with established cardiovascular disease.
Added Zepbound (tirzepatide) as an FDA-approved drug for chronic weight management to the policy.
Added Wegovy (semaglutide) to policy as an FDA-approved drug for chronic weight management.
Clarified pediatric coverage additions for Qsymia and brand orlistat and added pediatric re-authorization criteria.
Updated adult weight-related comorbid condition criteria to expand and rename the list of qualifying comorbidities (e.g., added asthma, COPD, coronary artery disease, dyslipidemia, knee osteoarthritis, MAFLD/NAFLD, PCOS; retained type 2 diabetes mellitus).
Added generic phentermine and generic extended-release phentermine/topiramate coverage criteria and required a trial of generic phentermine and phentermine/topiramate ER before branded Qsymia.
Clarified that the medications listed in this policy are subject to the product's FDA dosage and administration prescribing information.
Coverage Criteria Initial and Continuation
Contrave (naltrexone/bupropion) — Initial Therapy (Adults)
Contrave (naltrexone/bupropion) — Initial Therapy (Adults): Covered when ALL of the following are met:
ALL of the following
- Individual is aged 18 years or older
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- Has a body mass index (BMI) ≥ 30 kg/m2 OR has a BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions (asthma; cardiovascular disease; chronic obstructive pulmonary disease; coronary artery disease; dyslipidemia; hypertension; knee osteoarthritis; metabolic-dysfunction associated steatotic liver disease/non-alcoholic fatty liver disease; obstructive sleep apnea; polycystic ovarian syndrome; type 2 diabetes mellitus)
- Medication is being used as an adjunct to a reduced-calorie diet and increased physical activity
- Dose limited to four Contrave 8 mg tablets per day (taken as two tablets in the morning and two tablets in the evening)
- Medication is not being used concurrently with other medications intended for weight loss (e.g., phentermine; phentermine and topiramate ER; benzphetamine; diethylpropion; phendimetrazine; Alli; Saxenda; Wegovy; Xenical; Zepbound)
Generic phentermine and topiramate extended-release — Initial Therapy
Generic phentermine and topiramate extended-release — Initial Therapy (Adults and Pediatrics): Covered when ALL of the following are met:
ALL of the following
- For adults: individual is aged 18 years or older
- For pediatric individuals: aged 12 to 17 years
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- For adults: BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions (listed above)
- For pediatric individuals: current BMI ≥ 95th percentile for age and sex
- Medication is being used as an adjunct to a reduced-calorie diet and increased physical activity
- Dose limited to one 15 mg/92 mg capsule daily
- Medication is not being used concurrently with other medications intended for weight loss (phentermine; Contrave; Saxenda; Wegovy; Xenical; Zepbound; Qsymia; benzphetamine; diethylpropion; phendimetrazine; Alli)
Benefit plans may exclude drugs for weight management; verify benefit applicability.
Qsymia (phentermine and topiramate ER) — Initial Therapy
Qsymia (phentermine and topiramate ER) — Initial Therapy (Adults and Pediatrics): Covered when ALL of the following are met (step requirement applies to adults and pediatric applicants):
ALL of the following
- For adults: individual is aged 18 years or older
- For pediatric individuals: aged 12 to 17 years
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- For adults: BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions (listed above)
- For pediatric individuals: current BMI ≥ 95th percentile for age and sex
- Medication is being used as an adjunct to a reduced-calorie diet and increased physical activity
- Has tried and had an inadequate response or intolerance to generic phentermine and topiramate extended-release (step requirement)
- Dose limited to one 15 mg/92 mg capsule daily
- Medication is not being used concurrently with other medications intended for weight loss (see list under generic phentermine and topiramate)
Qsymia is contraindicated in pregnancy; topiramate component associated with increased risk of oral clefts with first-trimester exposure.
Wegovy (semaglutide) and Saxenda (liraglutide) — Initial Therapy
Wegovy (semaglutide) and Saxenda (liraglutide) — Initial Therapy (Adults and Pediatrics): Separate age-specific criteria apply:
ALL of the following
Wegovy — Adults
- Individual is aged 18 years or older
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions (listed above)
- Medication is being used as an adjunct to a reduced-calorie diet and increased physical activity
- Dose limited to 2.4 mg once weekly
- Medication is not being used concurrently with other medications intended for weight loss (see list)
Wegovy — Pediatrics
- Individual aged 12 to 17 years
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- Current BMI ≥ 95th percentile for age and sex
- Medication is being used as an adjunct to a reduced-calorie diet and increased physical activity
- Dose limited to 2.4 mg once weekly (pediatric quantity note may apply)
Wegovy — MACE risk reduction (Adults with established CVD)
- Adult aged ≥ 45 years with BMI ≥ 27 kg/m2 and established cardiovascular disease
- Medication is used in combination with optimized drug therapy for established cardiovascular disease
- Dose limited to 2.4 mg once weekly
- Medication is not being used concurrently with other weight-loss medications
SELECT trial evidence supports Wegovy for reduction of major adverse cardiovascular events in this population; confirm patient meets trial-aligned criteria (age, BMI, established CVD).
Saxenda — Adults and Pediatrics
- Follow agent-specific dosing: titrate to 3 mg daily for Saxenda; used as an adjunct to diet and activity
- Adult criteria: age ≥ 18 years; BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions
- Pediatric criteria: aged 12 to 17 years with BMI ≥ 95th percentile for age and sex
- Medication is not used concurrently with other weight-loss medications
Saxenda has a boxed warning regarding rodent thyroid C-cell tumors and is contraindicated in individuals with personal or family history of MTC or MEN2.
Xenical (orlistat) — Initial Therapy
Xenical (orlistat) — Initial Therapy and Dosing (Adults and Pediatrics): Covered when ALL of the following are met:
ALL of the following
- For adults: aged 18 years or older
- For pediatric individuals: aged 12 to 17 years
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- For adults: BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions
- For pediatric individuals: current BMI ≥ 95th percentile for age and sex
- Medication is used as an adjunct to a reduced-calorie diet and increased physical activity
- Dose limited to three 120 mg capsules daily (one capsule three times a day)
- Medication is not used concurrently with other medications intended for weight loss (see list)
Zepbound (tirzepatide) — Initial Therapy and OSA indication
Zepbound (tirzepatide) — Initial Therapy and OSA-specific Indication (Adults): Covered when ALL of the following are met:
ALL of the following
- Individual is aged 18 years or older
- Has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
- BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with one or more weight-related comorbid conditions
- For OSA-specific indication: sleep study within past 12 months shows apnea-hypopnea index ≥ 15 events/hour
- For OSA-specific indication: NOT diagnosed with central sleep apnea with percent central apneas/hypopneas ≥ 50% or Cheyne-Stokes respiration
- Medication is being used as an adjunct to a reduced-calorie diet and increased physical activity
- Dose limited to 15 mg once weekly (15 mg limit for OSA indication)
- Medication is not being used concurrently with other medications intended for weight loss (see list)
General coverage criteria (trial-aligned)
General coverage criteria (trial-aligned) — applies to all agents listed above: Covered when ALL of the following are met:
ALL of the following
- Patient has engaged in a trial of behavioral modification and dietary restriction for the required duration (generally 3 months; see agent-specific criteria)
- Patient selection and baseline characteristics align with pivotal trial populations (age ranges, BMI thresholds, comorbid conditions)
- Medication is used as an adjunct to a reduced-calorie diet and increased physical activity
- Dosing and titration follow FDA prescribing information and agent-specific dose limits
- Concurrent use with other weight-loss medications is not permitted
- Benefit plan applicability: many benefit plans exclude drugs for weight management; verify benefit prior to authorization
Combined initial and reauthorization criteria (summary)
Combined initial and reauthorization criteria — Summary of reauthorization thresholds and duration:
ALL of the following
- Non-formulary exception reviews and authorization durations may be approved up to 12 months where permitted by the benefit plan
- Wegovy reauthorization (adults): clinical benefit/response demonstrated as weight loss ≥ 5% of baseline body weight after 7 months of treatment and patient able to tolerate maintenance dose
- Wegovy reauthorization (pediatrics): follows agent-specific reauth standards and pediatric dosing notes
- Saxenda reauthorization: weight loss ≥ 4% of baseline body weight after 16 weeks of treatment and patient tolerates maintenance dose (pediatric reauth criteria apply where relevant)
- Qsymia reauthorization: weight loss ≥ 5% of baseline body weight after 26 weeks of treatment
- Contrave reauthorization: weight loss ≥ 5% of baseline body weight after 15 weeks of treatment
- Xenical reauthorization: weight loss ≥ 5% of baseline body weight after 6 months of treatment
- Zepbound and other agents: reauthorization may follow documentation of clinical response (weight loss and tolerability) and may be approved up to 12 months when benefit allows
At reauthorization, continued adherence to reduced-calorie diet and increased physical activity must be documented; trials/thresholds mirror those used in pivotal studies.
Drugs for weight management are excluded under many benefit plans. Refer to the applicable benefit plan document to determine benefit availability and specific terms, conditions, and limitations of coverage.
Concurrent-use restrictions: The medications listed in this policy must not be used concurrently with other medications intended for weight loss (including but not limited to phentermine; phentermine and topiramate ER; benzphetamine; diethylpropion; phendimetrazine; Alli; Contrave; Qsymia; Saxenda; Wegovy; Xenical; Zepbound).
Pregnancy and teratogenicity: Qsymia (phentermine/topiramate) is contraindicated in pregnancy due to risk of fetal harm (oral clefts associated with topiramate). Pregnancy testing and appropriate counseling should be performed per product labeling.
MTC / MEN2 contraindication: GLP-1 receptor agonists and GLP-1/GIP agents (e.g., Saxenda, Wegovy, Zepbound) carry boxed warnings from rodent data for thyroid C-cell tumors and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Off-label / outside-studied-context caution: Use of these agents outside the studied trial populations, doses, or indications (including combinations) should be approached cautiously and is considered investigational unless supported by evidence and benefit plan language.
Initial Therapy Criteria (Agent-Specific)
INITIAL THERAPY CRITERIA
Agent-specific initial coverage requires meeting age, behavioral trial, BMI (or pediatric percentile), adjunctive lifestyle use, dose limits, and no concurrent weight-loss drug use.
ALL of the following
- age: Age criteria per agent (adult or pediatric as specified)see agent-specific nodes
- behavioral_trial: 3-month trial of behavioral modification and dietary restriction>=3 months
- bmi: BMI >=30 or >=27 with comorbidity for adults; BMI >=95th percentile for pediatricssee agent
- adjunctive_use: Used as adjunct to reduced-calorie diet and increased physical activity
- dose_limit: Agent-specific dose limits apply (see policy)see agent
- concurrent_use: Not used concurrently with other weight-loss medications
Initial therapy notes
Initial therapy trial designs and titration schemes from pivotal trials.
See trial descriptions
Pediatric study used 56-week duration
Multiple 56-week trials
Initial therapy
Initial therapy considerations reflect trial titration schedules and baseline eligibility.
Trials required lifestyle intervention beginning at first dose.
Initial therapy (summary)
Initial authorization historically requires evidence of behavioral modification and dietary restriction; pediatric trial duration for behavioral modification was shortened from 4 to 3 months for certain drugs.
Updates in 2025 expanded qualifying comorbidities list.
Continuation / Re-authorization Criteria
CONTINUATION CRITERIA
Re-authorization is contingent on demonstrated clinical benefit/response and continued lifestyle adherence.
ALL of the following
- weight_response_adult_contrave: Weight loss >=5% baseline body weight after 15 weeks of treatment (Contrave)>=5% at 15 weeks
- weight_response_other_adults: Weight loss >=5% baseline body weight after 26 weeks of treatment (many other agents)>=5% at 26 weeks
- pediatric_reauth: For pediatric patients (12–17) on phentermine/topiramate agents: weight loss >=5% baseline BMI after 26 weeks>=5% BMI at 26 weeks
- ongoing_lifestyle: The individual continues to adhere to a reduced-calorie diet and increased physical activity
Continuation / Re-authorization
Continuation/re-authorization requires demonstration of clinical benefit at drug-specific timepoints and adherence to diet and activity; approvals frequently issued for 1 year.
Typical approval length: 1 year
Continuation therapy
Continuation generally aligns with trial maintenance phases where clinically meaningful weight loss is achieved and adverse effects are tolerable.
Trials included maintenance dosing periods of 52+ weeks after titration.
Reauthorization (historical thresholds summary)
Reauthorization requirements exist and have been historically defined per drug (weight-loss response thresholds and tolerability).
These thresholds were part of prior updates and retained unless superseded.
Coding, BMI Thresholds, and Key Values
Provider Actions, Documentation, and Prior Authorization
Authorization length limits
Initial authorization lengths vary by product. Non‑formulary exception reviews for any drug listed may be approved up to 12 months. Routine initial approvals by product: Contrave — as specified in product criteria; generic phentermine and phentermine/topiramate ER (including Qsymia) — up to 6 months; Saxenda — up to 4 months; Wegovy and Zepbound for chronic weight management — up to 7 months; Xenical and brand orlistat — up to 6 months. Follow the product's FDA dosing and administration prescribing information when requesting authorization.
Re‑authorization requirements (drug‑specific)
Re‑authorization requires objective evidence of clinical benefit at drug‑specific timepoints. Examples: weight loss ≥5% of baseline body weight after 26 weeks for most adult agents (eg, Contrave, Qsymia, generic phentermine/topiramate ER); Saxenda—weight loss ≥4% after 16 weeks and ability to tolerate maintenance dose; Wegovy—weight loss ≥5% after ~7 months and ability to tolerate maintenance dose; Zepbound—weight loss ≥5% after 7 months and ability to tolerate up to 15 mg weekly. Pediatric re‑auth criteria use percent change in baseline BMI (not body weight) and include lower percent thresholds for some agents per product criteria.
Prior authorization requirement — documentation expectations
Prior authorization is required for the weight‑management drugs listed in this policy. Requests must include indication, baseline body weight and BMI, documentation of a trial of behavioral modification/dietary restriction (typically ≥3 months unless pediatric criteria specify otherwise), relevant weight‑related comorbidities, current medication dose and plan, and evidence of prior drug trials when the policy requires (for example, trial of generic phentermine and phentermine/topiramate ER is required prior to branded Qsymia).
Concurrent weight‑loss medication exclusion (do not co‑prescribe)
These agents must not be used concurrently with other medications intended for weight loss. Concurrent use with other prescription or OTC weight‑loss agents (including generic phentermine, phentermine/topiramate ER, benzphetamine, diethylpropion, phendimetrazine, Contrave, Qsymia, Saxenda, Wegovy, Xenical/brand orlistat, and Zepbound) will result in denial of the request.
- phentermine
- phentermine and topiramate ER (generic and branded Qsymia)
- benzphetamine
- diethylpropion
- phendimetrazine
- Contrave (naltrexone/bupropion)
- Qsymia (phentermine/topiramate ER)
- Saxenda (liraglutide)
- Wegovy (semaglutide)
- Xenical / brand orlistat
- Zepbound (tirzepatide)
Contraindicated conditions for GLP‑1/GIP agents
Screen for contraindicated conditions for GLP‑1/GIP receptor agonists. These products (eg, Saxenda, Wegovy, Zepbound) carry boxed warnings regarding thyroid C‑cell tumors and are contraindicated in individuals with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Document absence of these histories in the medical record prior to authorization.
OSA diagnostic documentation for Zepbound
For Zepbound when requested for the OSA indication, include a sleep study (polysomnography) report performed within the prior 12 months documenting an apnea‑hypopnea index (AHI) ≥15 events/hour. Also document that central sleep apnea (≥50% central events) and Cheyne‑Stokes respiration are not present.
Supporting clinical documentation
Support requests with prior clinical documentation: prior trials of indicated agents (including required step trials), prior lifestyle intervention attempts, baseline and on‑treatment weights/BMI, comorbidity history, and dose‑tolerance information. When policy requires a documented prior trial (for example, trial of generic phentermine and phentermine/topiramate ER before Qsymia), include treatment dates, doses, and reason for discontinuation if applicable.
Step therapy requirement for Qsymia
Qsymia requires step therapy: trial and inadequate response or intolerance to generic phentermine and to generic phentermine/topiramate extended‑release (when available) are required prior to coverage of the branded product. Follow sequencing and coverage guidance in the policy when submitting requests.
Adjunctive therapy and dosing notes
Adjunctive therapy: all drugs are approved only as adjuncts to a reduced‑calorie diet and increased physical activity — document the dietary/physical activity plan. Observe product dosing limits (for example, Saxenda titration to and maintenance at 3 mg daily; Wegovy maintenance at 2.4 mg weekly; Zepbound maintenance up to 15 mg weekly) and include dose‑tolerance evidence when required for re‑authorization.
Pediatric step/re‑authorization notes
Pediatric‑specific requirements: where pediatric indications apply (eg, Qsymia, Saxenda, Wegovy, Xenical), ensure trials of behavioral modification are consistent with pediatric timing (often shortened to 3 months), document baseline BMI percentile (≥95th percentile for obesity), and apply pediatric re‑authorization thresholds based on percent change in baseline BMI. Include pediatric quantity limits or dose caps as noted in product guidance.
Step Therapy and Fail-First Requirements
| Step | Requirement | Applies to |
|---|---|---|
| 1 | Trial of generic phentermine and topiramate extended‑release with inadequate response or intolerance prior to Qsymia; dose limit for generic formulation: one 15 mg/92 mg capsule daily | Adults (and pediatric where applicable per product labeling) — required before branded Qsymia |
| Topic | Policy note |
|---|---|
| Adjunctive use | Medications are required to be used as an adjunct to a reduced‑calorie diet and increased physical activity (policy reiterates diet/exercise counseling as part of therapy). |
| Dose limits | Dose limits are specified per product (examples: Wegovy maintenance dose limited to 2.4 mg once weekly; Saxenda maintenance dose limited to 3 mg once daily; generic phentermine/topiramate ER limited to one 15 mg/92 mg capsule daily). |
| Explicit sequencing | Policy operationalizes a required trial of generic phentermine and phentermine/topiramate ER prior to branded Qsymia (explicit step for Qsymia); other agents reference adjunctive lifestyle use and dose limits but do not specify additional multi‑step drug sequencing in the cited chunks. |
| Documentation element | Requirement |
|---|---|
| Behavioral modification trial | Medical record must document a trial of behavioral modification and dietary restriction (≥3 months) prior to initiating therapy or as required for re‑authorization evidence. |
| Baseline measures | Documentation should include baseline body weight and BMI (or baseline BMI percentile for pediatrics) to enable assessment of percent weight/BMI change at re‑authorization. |
| Re‑authorization response | Re‑authorization requires demonstration of drug‑specific clinical benefit (examples: ≥5% baseline body weight for many agents after specified treatment durations; Saxenda ≥4% at 16 weeks; Wegovy ≥5% at 7 months; Qsymia/Xenical/Zepbound thresholds as specified in policy). |
| Requirement | Least‑cost alternative required | Notes |
|---|---|---|
| Trial of least‑cost alternative prior to branded agent | Covered — trial of generic phentermine and phentermine/topiramate ER is required prior to coverage of branded Qsymia (explicit in 2025 update). | Policy update clarifies generic formulations and generic phentermine/topiramate ER must be tried first; concurrent use with listed policy agents is disallowed. |
Quantity Limits and Dose Caps
Site of Care
Office/outpatient prescribing (no site limitation)
Medications are prescribed for outpatient chronic weight management and the policy does not specify any explicit site‑of‑care limitations.
Home administration for weekly injectables and oral agents
Drugs are typically administered by the patient at home (self‑administered subcutaneous weekly injections for products like Wegovy and Zepbound, and oral agents such as orlistat); site of care is generally home with outpatient follow‑up.
Definitions and Appendix References
Background
Excess body weight is associated with increased risk of type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, and greater overall mortality. Pharmacologic therapy for chronic weight management is intended as an adjunct to a documented trial of behavioral modification and a reduced‑calorie diet with increased physical activity when those measures alone have been insufficient. Clinical trials of the agents in this policy demonstrated clinically meaningful weight loss (commonly measured at 6–72 weeks depending on the product) and informed the drug‑specific initiation, dosing, and reauthorization thresholds included in this policy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.